Researchers in the USA are testing an experimental vaccine that could combat multiple types of cancer.

Researchers at the University of Amherst, Massachusetts, have developed an experimental vaccine based on nanoparticles that has demonstrated the ability to prevent several aggressive types of cancer, including melanoma, pancreatic cancer, and triple-negative breast cancer, in mice. The study showed that the vaccine maintained up to 88% of the animals without tumors, simultaneously activating multiple pathways of the immune system and generating strong T cell responses. This vaccine surpassed the performance of traditional formulations, which failed to protect animals from tumor development. The lead researcher, Prabhani Atukorale, emphasized the importance of the vaccine's ability to create systemic immune memory, allowing the body to recognize and destroy cancer cells in the long term. By using inactivated tumor cells, the vaccine was able to provide protection against multiple types of cancer without requiring customized genetic sequencing. The tumor rejection rate was 88% for pancreatic cancer, 75% for breast cancer, and 69% for melanoma.